Pfizer Marketing Scheme Stirs Concern_NYT / Corporate Responsibility Movement Puts PhRMA on Notice_ ICCR Mon, 7 Mar 2005 The New York Times reports that Pfizer is planning to lock up the market for heart treaments by bundling its new drug (toretrapib, which is still in experimental stage of development) to…
Corporate Welfare Runs Amok – NYT Editorial Sun, 30 Jan 2005 The administration has gone another step toward doing away with corporate taxes – by offering a “tax holiday” to America’s richest multinationals. The 35% corporate tax rate is being winnowed down to the “puny rate” of 5.25% for corporations…
Peter R. Breggin, M.D. 101 East State Street, No. 112 Ithaca, New York 14850 www.breggin.com Phone: 607 272 5328 Fax: 607 272 5329 January 12, 2005 An Examination of Eli Lilly and Company’s Contentions that the BMJ Prozac Documents were Never Missing and Have No Significance A report by Peter…
Bad Medicine: A Gift for Drug Makers–Malpractice Bill Shields Drugmakers Sat, 15 Jan 2005 Knowledgable critics – among them practicing physicians, health care analysts, medical journal editors, journalists, and lay citizens–have reached the conclusion that America’s for-profit health care system – which eats up 16% of the budget–has failed to…
2/3 Institute of Medicine AIDS research panel have Conflicts of Interst – Assoc Press Thu, 17 Mar 2005 On Feb 25, the New York Times reported that 10 of 32 FDA panelists determining whether to recommend that COX 2 painkillers should allowed to be marketed despite the documented increased risk…
Efforts to promote Cymbalta for Fibromyalgia symptoms Wed, 20 Oct 2004 Cymbalta (duloxetine) was approved by the FDA as a treatment for depression in adults. No doubt in an effort to expand the drugs’ market, Eli Lilly tested the drug in patients with fibromyalgia. The published report claims women who…
Govt Prozac study Recommends MANDATORY Screening & Drugs – “Overdosed America”_OpEd NYT Sun, 19 Sep 2004 FDA’s Review of Safety & Efficacy Concerns in Anti-Depressant Use by Children is the subject of a second Congressional hearing by the House Energy & Commerce Subcommittee on Oversight / Investigations on September 23,…
18% decrease SSRI use in Youth – NYT / Suicide Risk Not New – Globe / Prozac no different Tue, 21 Sep 2004 The FDA failed to stop drug manufacturers from flooding the air waves and the scientific literature with false and scientifically invalid claims-based on partial data. “The FDA…
FDA’s Waiting Game Exposes Children to Preventable Risks Comments by Vera Hassner Sharav President The Alliance for Human Research Protection Submitted to FDA Advisory Committee Psychopharmacological Drugs Advisory Committee and Pediatric Subcommittee Drugs Advisory Committee September 13-14, 2004 Meeting RE: Suicidality Associated with Antidepressant Drug Treatment The Alliance for Human…
ALLIANCE FOR HUMAN RESEARCH PROTECTION (AHRP) 142 West End Ave. Suite 28P, New York, NY 10023 ***PRESS RELEASE*** September 11, 2004 Contact: Vera Hassner Sharav, President, AHRP Tel. No: 212-595-8974 Cell: 917-375-5083 ***AHRP PRESS BRIEFING*** Re: Antidepressants and suicide-related risks for children When: September 14, 2004, 12:00 P.M. Where: Holiday…
US Epidemic: Controlled Prescription Drug Abuse–Teen Drug Abuse Triples in 10 Years_CASA Sat, 9 Jul 2005 “Our nation is in the throes of an epidemic of controlled prescription drug abuse and addiction,” said Joseph A. Califano, Jr., CASA’s chairman and president and former U.S. Secretary of Health, Education and Welfare….
Law Suits and Court Decisions Sep 15 2005: FDA Amicus Curiae–Kallas–claims FDA infallibility pre-empts state safety laws (warning: 1.6 MB file) Aug 6 2004: Psychiatrist Scolds the APA After Winning Distinguished Fellow Award/ NYC Sues 44 Pharma Companies Aug 5: Pfizer issues prosecutors a manual to defend drug – Star…
